去甲氧柔红霉素治疗急性髓细胞性白血病临床观察  

Clinical observation of treatment of acute myeloid leukemia with idarubicin

作　　者：叶隽[1] 李静[1] 

机构地区：[1]安徽省蚌埠市第三人民医院血液科,233000

出　　处：《蚌埠医学院学报》2012年第9期1051-1052,共2页Journal of Bengbu Medical College

摘　　要：目的:观察以去甲氧柔红霉素(IDA)为主的化疗方案治疗急性髓细胞性白血病(AML)的疗效和不良反应。方法:39例AML患者,随机分为2组。对照组16例采用柔红霉素+阿糖胞苷(Ara-C)治疗,治疗组23例采用IDA+Ara-C治疗,观察治疗后缓解率及不良反应。结果:2组治疗完全缓解率分别为82.6%和43.8%,总有效率分别为91.3%和62.5%,临床严重感染率分别为40.0%和41.7%。2组总有效率差异有统计学意义(P<0.05),但2组的严重感染发生率差异无统计学意义(P>0.05)。结论:以IDA组成的联合化疗方案治疗AML疗效较好。Objective：To investigate the clinical effects and toxic reaction of idarubicin（IDA） on the acute myeloid leukemia（AML）. Methods：Thirty-nine patients with AML were randomly divided into treatment group,which were treated with IDA and Ara-C（23 cases） and control group which were treated with daunorubicin combined with Ara-C（16 cases）.The remission rates and toxic reaction of two groups were observed. Results：The complete remission,total effective and severe infection rates of the treatment and control group were 82.6%and 43.8%,91.3% and 62.5% and 40.0% and 41.7%,respectively.The difference of total effective of two groups was statistical significant（P〈0.05）,but for not severe infection rates（P〉0.05）. Conclusions：The effects of treatment of AML with chemotherapeutic scheme containing IDA are good.

关 键 词：白血病 髓样 急性 去甲氧柔红霉素 柔红霉素 

分 类 号：R733.71[医药卫生—肿瘤]